InMed Pharmaceuticals Inc.INM
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · inmedpharma.com
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Key ratios
FCF / Sales
-178.3%TTM
2025
-157.1%2024
-152.1%
Net margin
-172.2%TTM
2025
-165.1%2024
-166.9%
ROA
-66.5%TTM
2026
-66.5%2025
-36.1%2024
-39.2%
ROE
-156.8%TTM
2026
-156.8%2025
-72.1%2024
-72.1%
Revenue growth
285.2%TTM
2025
7.5%2024
11.2%
Recent news
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Track INM in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer